Imricor Medical Systems clears FDA milestones toward US commercial launch

A string of world-first MRI-guided cardiac ablation procedures and successive FDA clearances have carried Imricor Medical Systems toward its long-awaited US commercial entry point, capped by a A$60 million raise to fund the launch.

31 May 2026 · 5 min read

Imricor Medical Systems, Inc (ASX: IMR) spent 2025 and early 2026 methodically clearing the regulatory and clinical milestones standing between it and a US commercial launch for its MRI-guided cardiac ablation platform. Saville Capital tracked the process closely from mid-2025, when the company's NorthStar software was submitted to the FDA, through a series of setbacks and breakthroughs that culminated in the company's first regulatory clearances.

World-first procedures build the clinical case

Through the second half of 2025, Imricor notched a series of clinical firsts that Saville Capital said were building momentum toward FDA approval. In October, the company completed the first Pulsed Field Ablation ever performed under real-time MRI guidance, validating its technology for integrating PFA energy with real-time visualisation, a step the fund noted was significant given atrial fibrillation ablations represent roughly 65-70% of all cardiac ablation procedures worldwide. In November, Imricor completed the world's first ischemic ventricular tachycardia ablation guided entirely by real-time MRI, at Amsterdam University Medical Centre, a procedure Saville Capital called "a watershed moment for the field of MRI-guided electrophysiology."

This milestone marks a critical step forward for IMR's VISABL-VT clinical trial, and a watershed moment for the field of MRI-guided electrophysiology. The successful procedure paves the way for broader clinical use of MRI-guided ablations.

Saville Capital, Monthly Report, November 2025

The FDA clearances arrive

The regulatory breakthrough came in January 2026. Saville Capital described the month as a watershed, with Imricor receiving its first two FDA clearances, for its Vision-MR Diagnostic catheter and its NorthStar 3D mapping software, enabling the company to commercially market NorthStar in the United States for the first time. The fund noted this also acted as a segue to broader discussions around commercially introducing the entire MRI-guided electrophysiology platform to the US market, with further clearances expected through the calendar year. Investors Mutual Limited captured the market's response in March 2026, noting the stock had continued its strong run over the past 12 months, up 24%, as it received FDA approval for NorthStar and announced a number of new US clinical trial sites.

Capital raised to fund the commercial launch

With regulatory clearance in hand, Imricor moved to fund its US go-to-market push. SG Hiscock & Company reported participating in a A$60 million capital raise in May 2026, priced at A$1.85 per share and strongly supported by institutional investors, leaving the company with approximately A$103 million in cash following completion. The fund said the raise significantly accelerates Imricor's growth strategy, providing capital to commercialise NorthStar in the US, advance regulatory approvals for the broader electrophysiology platform, complete key clinical trials, expand into the Middle East, and continue development of its Pulsed Field Ablation program.

The raise meaningfully strengthens Imricor's strategic position by providing the capital required to move from regulatory and clinical validation toward commercial scale.

SG Hiscock & Company, Monthly Report, May 2026

What managers are watching next

With NorthStar now clearable for commercial marketing in the US and a fully funded balance sheet following the May raise, the next catalysts fund managers are tracking are the pace of additional FDA approvals across the remaining capital equipment and consumable devices, enrolment progress in the VISABL-AFL and VISABL-VT clinical trials, and how quickly the newly cleared products translate into actual US hospital site engagements and revenue.